Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals has resubmitted a New Drug Application to the U.S. FDA for TLX101-Px (Pixclara), an F-18 FET PET imaging agent designed to differentiate recurrent or progressive glioma from treatment-related changes in adult and pediatric patients. The filing includes additional data and statistical analyses requested by regulators, which the company believes address prior concerns that led to an earlier Complete Response Letter.
TLX101-Px, which has Fast Track and Orphan Drug designations, targets LAT1/LAT2 transporters and could serve as a companion diagnostic for Telix’s LAT1-targeting GBM therapy candidate TLX101-Tx, now in pivotal trials. With no FDA-approved targeted amino acid PET agent currently available for brain cancer imaging in the U.S., a potential approval would fill a significant diagnostic gap in glioma management and could strengthen Telix’s strategic position in neuro-oncology radiopharmaceuticals.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals and related medical technologies for oncology and rare diseases. Headquartered in Melbourne with operations across the U.S., Europe, Brazil, Canada, the U.K. and Japan, Telix markets the PSMA-PET imaging agents Illuccix and Gozellix and is listed on both the ASX and Nasdaq.
The company’s pipeline includes TLX101-Px and TLX101-Tx for glioma and glioblastoma, which remain investigational and have not yet received marketing authorization in any jurisdiction. Telix aims to leverage its radiopharmaceutical expertise to expand targeted imaging and therapeutic options in high unmet-need cancer indications worldwide.
YTD Price Performance: 0.80%
Average Trading Volume: 2,952,509
Technical Sentiment Signal: Sell
Current Market Cap: A$3.83B
Learn more about TLX stock on TipRanks’ Stock Analysis page.